Analysts Set AstraZeneca PLC (LON:AZN) Target Price at £153.33

Shares of AstraZeneca PLC (LON:AZN) have received a consensus rating of “Moderate Buy” from the six brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is £153.33.

AZN has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft reissued a “sell” rating and set a £115 target price on shares of AstraZeneca in a research note on Friday, June 26th. Jefferies Financial Group reaffirmed a “buy” rating and set a £180 price objective on shares of AstraZeneca in a report on Friday, June 26th. Finally, Citigroup cut shares of AstraZeneca to a “buy” rating in a research report on Friday, July 10th.

AstraZeneca Trading Down 0.1%

Shares of AZN stock opened at £126.88 on Tuesday. AstraZeneca has a 52-week low of £105.24 and a 52-week high of £157.32. The company has a debt-to-equity ratio of 71.66, a quick ratio of 0.59 and a current ratio of 0.91. The firm has a market capitalization of £196.78 billion, a PE ratio of 19.11, a PEG ratio of 0.86 and a beta of 0.23. The stock has a fifty day simple moving average of £135.25 and a two-hundred day simple moving average of £140.74.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.